<?xml version="1.0" encoding="UTF-8"?>
<p id="Par49">Secondary endpoints include ORR on pre-resection imaging at day 42 according to the RECIST v1.1 criteria and pathologic response rate on evaluation of the resected specimen. Exploratory endpoints are PFS rate and OS at day 126 and every 4â€‰months thereafter and identity of biomarkers of response to nivolumab and ipilimumab using high-throughput technologies.</p>
